24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
5 citations
,
January 2018 in “Interdisciplinary sciences: computational life sciences” Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.
18 citations
,
October 2021 in “Frontiers in Physiology” Lipocalin-Type Prostaglandin D2 Synthase (L-PGDS) is a protein that plays many roles in the body, including sleep regulation, pain management, food intake, and protection against harmful substances. It also affects fat metabolism, glucose intolerance, cell maturation, and is involved in various diseases like diabetes, cancer, and arthritis. It can influence sex organ development and embryonic cell differentiation, and its levels can be used as a diagnostic marker for certain conditions.
September 2017 in “Hair transplant forum international”
L-PGDS has specific binding sites for its functions and could help in drug delivery system design.
June 2021 in “F1000Research” Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.
12 citations
,
October 2012 in “International Braz J Urol” Finasteride effectively and safely treats recurrent priapism in children and adolescents with sickle cell disease.
August 2002 in “Inpharma Weekly” 2 citations
,
August 2011 in “Cochrane Database of Systematic Reviews” February 2023 in “Sexual Medicine Reviews”
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
4 citations
,
July 2020 in “Research Square (Research Square)” The research helps understand how finasteride works and aids drug development.
9 citations
,
April 2020 in “The Journal of Urology” 5α-Reductase inhibitors don't cause depression.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
March 2010 in “The Journal of Urology” Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
253 citations
,
April 2009 in “Journal of Biological Chemistry” p2y5, now called LPA6, is a receptor important for human hair growth.
January 2014 in “프로그램북(구 초록집)” 5AR inhibitors like finasteride and dutasteride improve hair growth and slow hair loss in male pattern baldness.
April 2007 in “Nature Clinical Practice Urology” Finasteride lowers PSA levels about the same whether taken at 1 mg or 5 mg daily.
20 citations
,
March 2005 in “Current Medicinal Chemistry” New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.
September 2005 in “日本医療薬学会年会講演要旨集” April 2011 in “The Journal of Urology” Finasteride effectively reduced priapism episodes in children with sickle cell disease without side effects.
March 2026 in “Actas Dermo-Sifiliográficas” Most dermatologists think post-finasteride syndrome is rare, possibly psychiatric, and needs more research.
April 2006 in “The Journal of Urology” Genetic variations may affect how well finasteride works for BPH patients.
3 citations
,
May 2014 in “Urologia Journal” 5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.
115 citations
,
March 2001 in “Baillière's best practice and research in clinical endocrinology and metabolism/Baillière's best practice & research. Clinical endocrinology & metabolism” Key enzymes control androgen levels, affecting hormone activity and potential treatments.
17 citations
,
November 1997 in “Andrology” Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
34 citations
,
December 2015 in “Neuroscience & Biobehavioral Reviews” Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.
3 citations
,
March 2018 in “European Urology Supplements” Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
October 2008 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” 5-alpha reductase inhibitors do not increase hip fracture risk.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.